3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
21
Meningioma
6
Gastro-enteropancreatic neuroendocrine tumor
6
Pheochromocytoma
3
Paraganglioma
3
Prostatic Neoplasms
2
Neuroblastoma
2
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Carcinoma, Merkel Cell
2
Adenoma, Islet Cell
2
Somatostatin Receptor-positive Neuroendocrine Tumor
1
Sarcoma, Synovial
1
Recurrence
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Metastatic Digestive System Neuroendocrine Tumor G1
1
Hypertension
1
Extensive Stage Small Cell Lung Cancer
1
Esthesioneuroblastoma, Olfactory
1
Disease Progression
1
Digestive System Neuroendocrine Tumor G1
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Neuroendocrine
1
Carcinoma
1
Interventions
olaparib
1
lutetium Lu 177 dotatate
1
enasidenib
1
Tomography, X-Ray Computed
1
Radionuclide Imaging
1
Positron-Emission Tomography
1
Ibuprofen
1
Electrocardiography
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esthesioneuroblastoma, Olfactory
×
lutetium Lu 177 dotatate
×
1 year
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled